Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) included Froedtert & The MCW of Wisconsin in its list of clinical sites. It is working on IDE pilot trial for Neuro-Spinal Scaffold. The people enrolled in the study are suffering from ‘acute spinal cord injury.’ It enrolled the first patient in last October. The study was conducted at the Barrow Neurological Institute and St. Joseph’s Hospital. The second patient was enrolled in January 2015. The treatment of the second enrollment is undergoing at Carolinas Medical Center in Charlotte, NC.
The new clinical site
The Neuro-Spinal Scaffold study includes only those patients who are suffering from spinal cord injury. The new clinical site supports level one trauma center located in Wisconsin. Invivo selected Froedtert as several patients from different places come here for treatment of spinal cord injury. The patients from northern Illinois, Wisconsin, and northern Michigan come here for treatment. Dr. Shekar Kurpad, MD, will be the Principal Investigator at Froedtert. He is a neurosurgery Professor at MCW. Expressing his views, Dr. Kurpad said that it is an honor to become a part of the innovative study.
Mark Perrin of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) said that the management, the research team and company is pleased to include MCW in the list of clinical sites. Also, it is encouraging to have Dr. Kurpad as Principal Investigator for IDE pilot study at MCW. He is the one to receive the Van Wagenen Fellowship, granted by the ‘American Association of Neurological Surgeons.’ Having such an experienced expert will strengthen research team. Invivo now has total seven sites for carrying its Neuro-Spinal Scaffold study.
IDE pilot study
Invivo’s IDE pilot trial is the first clinical study of Neuro-Spinal Scaffold. It has received the approval from the U.S.FDA. The primary objective is to collect initial data of effectiveness and safety. The treatment will be evaluated in five enrollments suffering from spinal cord injury.